In addition to mechanistic studies, two distinct approaches toward therapy were explored in the psap KO model: pharmacological modulation of inflammatory pathways via the FDA-approved multiple sclerosis drug MMF, and genetic rescue via acid sphingomyelinase (smpd1) knockout. Here, SMPD1 is linked to multiple sclerosis.